Unbound Prime | J Hepatol

(J Hepatol[TA])

14,039 results

Clarification of the ELM score performance tables. [Letter]
J Hepatol. 2026 Oct 17. [Online ahead of print]Giuffrè M, Colecchia A, Dajti EJH
Publisher Full Text (DOI)

From the Editor's desk... [Editorial]
J Hepatol. 2026 Nov; 85(5):809-812.Newsome PN, Tacke F, … Ratziu VJH
Publisher Full Text (DOI)

Interpreting HCC risk and HBsAg clearance in the long-term PAGE-B cohort. [Letter]
J Hepatol. 2026 Oct 15. [Online ahead of print]Papatheodoridis GV, Sypsa VJH
Publisher Full Text (DOI)

Surveillance of patients at risk of liver cancer: Expert Opinions - authors' reply. [Letter]
J Hepatol. 2026 Oct 14. [Online ahead of print]Innes H, Jepsen P, … Cheuk-Fung Yip TJH
Publisher Full Text (DOI)

Abnormal left ventricular mass as a prognostic marker for outcomes in infants and children with cirrhosis. [Journal Article]
J Hepatol. 2026 Oct 12. [Online ahead of print]Bashir DA, Thadani S, … Desai MSJH
CONCLUSIONS: LVMI is a strong predictor of morbidity and mortality, serving as a prognostic marker in children with cirrhosis. Incorporating LVMI into PELD-Cr/MELD may enhance risk stratification and organ allocation.
Publisher Full Text (DOI)

First-line durvalumab and tremelimumab in poor-prognosis unresectable hepatocellular carcinoma: Phase IIIb single-arm SIERRA study. [Journal Article]
J Hepatol. 2026 Oct 06. [Online ahead of print]Chan SL, Kudo M, … Rimassa LJH
CONCLUSIONS: SIERRA safety and efficacy findings were indicative of a favourable risk-benefit profile for STRIDE in this participant population with a high unmet need.
Publisher Full Text (DOI)

Effects of MASH risk genotypes on resmetirom efficacy in patients with MASH and fibrosis. [Journal Article]
J Hepatol. 2026 Oct 05. [Online ahead of print]Chalasani NP, Taub R, … Anstee QMJH
CONCLUSIONS: Resmetirom's effects on MASH, liver fibrosis, MRI-PDFF, and MASH biomarkers in the MAESTRO-NASH trial were not significantly impacted by the presence of common MASH risk genotypes. This suggests that resmetirom's mchanism of action is not affected by hepatic defects conferred by prominent MASH genetic risk pathways.
Publisher Full Text (DOI)

Temporal assessment of spatial and single-cell transcriptomes identifies CD226-NECTIN2 T cell-cholangiocyte interaction in bile duct inflammation. [Journal Article]
J Hepatol. 2026 Oct 05. [Online ahead of print]Jördens MS, Nordhus KS, … Melum EJH
CONCLUSIONS: By combining spatial transcriptomics and scRNA-seq in NOD.c3c4 mice, we generated a pipeline for in-depth identification of potential disease relevant genes and interaction partners. The T cell-cholangiocyte interaction CD226-NECTIN2 was identified, functionally validated and detected in human disease highlighting this interaction as a possible future treatment target.
Publisher Full Text (DOI)

Survival outcomes after liver transplantation in acute-on-chronic liver failure: A prospective study. [Journal Article]
J Hepatol. 2026 Sep 30. [Online ahead of print]Gustot T, Bernal W, … Investigators of the CHANCE study groupJH
CONCLUSIONS: Patients with severe ACLF who underwent LT showed markedly better survival outcomes than those who were declined. Patients with five or six organ failures had high risk of post-LT death cautioning against routine LT in this population.
Publisher Full Text (DOI)

Log in to Prime